Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Total Liabilities (2016 - 2023)

Rapid Therapeutic Science Laboratories' Total Liabilities history spans 8 years, with the latest figure at $4.8 million for Q2 2023.

  • For Q2 2023, Total Liabilities fell 10.01% year-over-year to $4.8 million; the TTM value through Jun 2023 reached $4.8 million, down 10.01%, while the annual FY2022 figure was $5.4 million, 50.66% up from the prior year.
  • Total Liabilities for Q2 2023 was $4.8 million at Rapid Therapeutic Science Laboratories, down from $4.9 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $5.6 million in Q1 2022 and bottomed at $278233.0 in Q1 2021.
  • The 5-year median for Total Liabilities is $3.2 million (2019), against an average of $3.1 million.
  • The largest annual shift saw Total Liabilities tumbled 84.62% in 2021 before it surged 1924.6% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $1.7 million in 2019, then fell by 9.33% to $1.5 million in 2020, then surged by 135.0% to $3.6 million in 2021, then skyrocketed by 50.66% to $5.4 million in 2022, then dropped by 10.8% to $4.8 million in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Total Liabilities are $4.8 million (Q2 2023), $4.9 million (Q1 2023), and $5.4 million (Q4 2022).